Greenwich Lifesciences CEO Snehal Patel acquires $44,030 in inventory

Following this transaction, Patel now straight owns 5,547,102 shares of the corporate. This acquisition displays Patel’s continued funding in Greenwich LifeSciences, a pharmaceutical firm based mostly in Stafford, Texas, which presently maintains a market capitalization of $172.33 million. InvestingPro evaluation reveals the inventory’s excessive volatility with a beta of three.3, whereas analysts have set a goal value of $38 per share. Uncover extra worthwhile insights and seven further ProTips with an InvestingPro subscription. Following this transaction, Patel now straight owns 5,547,102 shares of the corporate. This acquisition displays Patel’s continued funding in Greenwich LifeSciences, a pharmaceutical firm based mostly in Stafford, Texas, which presently maintains a market capitalization of $172.33 million. InvestingPro evaluation reveals the inventory’s excessive volatility with a beta of three.3, whereas analysts have set a goal value of $38 per share. Uncover extra worthwhile insights and seven further ProTips with an InvestingPro subscription.

In different current information, Greenwich LifeSciences reported outcomes from its Annual Assembly of Stockholders. The assembly resulted within the re-election of all 5 director nominees, indicating robust help for the corporate’s management, with over 7.8 million votes for every director. The corporate’s impartial registered public accounting agency, RBSM, LLP, was additionally ratified for the fiscal yr ending December 31, 2024, receiving over 9 million votes in favor.

A big modification to the corporate’s 2019 Fairness Incentive Plan was authorized, rising the variety of shares reserved for issuance beneath the plan to 4 million from the earlier 1.5 million shares. This proposal obtained over 8 million votes in favor.

These current developments replicate the shareholders’ help for Greenwich LifeSciences’ strategic initiatives. InvestingPro evaluation signifies that whereas the corporate shouldn’t be presently worthwhile, analysts have set an bold value goal of $38. The corporate maintains robust liquidity with a present ratio of 6.91, indicating strong short-term monetary stability.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.